Literature DB >> 10577702

Postoperative irradiation of minor salivary gland malignancies of the head and neck.

Q T Le1, S Birdwell, D J Terris, E C Gabalski, A Varghese, W e Fee, D R Goffinet.   

Abstract

OBJECTIVES: (1) To review the Stanford experience with postoperative radiotherapy for minor salivary gland carcinomas of the head and neck. (2) To identify patterns of failure and prognostic factors for these tumors.
MATERIALS AND METHODS: Fifty-four patients with localized tumors were treated with curative intent at Stanford University between 1966 and 1995. The 1992 AJCC staging for squamous cell carcinomas was used to retrospectively stage these patients. Thirteen percent had stage I, 22% stage II, 26% stage III, and 39% stage IV neoplasms. Thirty-two patients (59%) had adenoid cystic carcinoma, 15 (28%) had adenocarcinoma, and seven (13%) had mucoepidermoid carcinoma. Thirty (55%) had positive surgical margins and seven (13%) had cervical lymph node involvement at diagnosis. The median follow-up for alive patients was 7.8 years (range: 25 months-28.9 years).
RESULTS: The 5- and 10-year actuarial local control rates were 91 and 88%, respectively. Advanced T-stage (T3-4), involved surgical margins, adenocarcinoma histology, and sinonasal and oropharyngeal primaries were associated with poorer local control. The 5- and 10-year actuarial freedom from distant metastasis were 86 and 81%, respectively. Advanced T-stage (T3-4), lymph node involvement at diagnosis, adenoid cystic and high-grade mucoepidermoid histology were associated with a higher risk of distant metastases. The 10-year cause-specific survival (CSS) and overall survival (OS) were 81 % and 63%, respectively. On multivariate analysis, prognostic factors affecting survival were T-stage (favoring T1-2), and N-stage (favoring NO). When T- and N-stage were combined to form the AJCC stage, the latter became the most significant factor for survival. The 10-year OS was 86% for stage I-II vs. 52% for stage III-IV tumors. Late treatment-related toxicity was low (3/54); most complications were mild and no cranial nerve damage was noted.
CONCLUSIONS: Surgical resection and carefully planned post-operative radiation therapy for minor salivary gland tumors is well tolerated and effective with high local control rates. AJCC stage was the most significant predictor for survival and should be used for staging minor salivary gland carcinomas.

Entities:  

Mesh:

Year:  1999        PMID: 10577702     DOI: 10.1016/s0167-8140(99)00084-5

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  15 in total

1.  Malignant minor salivary gland tumors: a retrospective study of 27 cases.

Authors:  Astrid L D Kruse; Klaus W Grätz; Joachim A Obwegeser; Heinz-Theo Lübbers
Journal:  Oral Maxillofac Surg       Date:  2010-12

2.  Outcome and management of rare high-grade "salivary" adenocarcinoma: the important role of adjuvant (chemo)radiotherapy.

Authors:  Claudia Scherl; Marlen Haderlein; Abbas Agaimy; Konstantinos Mantsopoulos; Michael Koch; Maximilian Traxdorf; Rainer Fietkau; Philipp Grundtner; Heinrich Iro
Journal:  Strahlenther Onkol       Date:  2019-07-26       Impact factor: 3.621

3.  Low-grade papillary adenocarcinoma of the palate: the significance of distinguishing it from polymorphous low-grade adenocarcinoma.

Authors:  Jacob B Hunter; Richard V Smith; Margaret Brandwein-Gensler
Journal:  Head Neck Pathol       Date:  2008-09-12

4.  125I brachytherapy alone for recurrent or locally advanced adenoid cystic carcinoma of the oral and maxillofacial region.

Authors:  M-W Huang; L Zheng; S-M Liu; Y Shi; J Zhang; G-Y Yu; J-G Zhang
Journal:  Strahlenther Onkol       Date:  2013-04-28       Impact factor: 3.621

5.  Radiation therapy in the treatment of minor salivary gland tumors.

Authors:  Lucas R Salgado; Daniel E Spratt; Nadeem Riaz; Paul B Romesser; Suzanne Wolden; Shyam Rao; Christine Chin; Julian C Hong; Richard Wong; Nancy Y Lee
Journal:  Am J Clin Oncol       Date:  2014-10       Impact factor: 2.339

6.  Expression and function of CXCR4 in human salivary gland cancers.

Authors:  Daisuke Uchida; Nobuyuki Kuribayashi; Makoto Kinouchi; Go Ohe; Tetsuya Tamatani; Hirokazu Nagai; Youji Miyamoto
Journal:  Clin Exp Metastasis       Date:  2012-07-31       Impact factor: 5.150

7.  Multi-modality Treatment and Survival in Sinonasal Minor Salivary Gland Tumors.

Authors:  Sina J Torabi; Todd Spock; Bruno Cardoso; Janet Chao; R Peter Manes; Benjamin L Judson
Journal:  J Neurol Surg B Skull Base       Date:  2019-04-01

8.  Sinonasal tract and nasopharyngeal adenoid cystic carcinoma: a clinicopathologic and immunophenotypic study of 86 cases.

Authors:  Lester D R Thompson; Carla Penner; Ngoc J Ho; Robert D Foss; Markku Miettinen; Jacqueline A Wieneke; Christopher A Moskaluk; Edward B Stelow
Journal:  Head Neck Pathol       Date:  2013-09-15

9.  Minor salivary gland carcinoma: a review of 35 cases.

Authors:  Georg Haymerle; Sven Schneider; Luke Harris; Theresia Häupl; Christian Schopper; Johannes Pammer; Matthaeus Ch Grasl; Boban M Erovic
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-10-23       Impact factor: 2.503

10.  Frequent downregulation of 14-3-3 sigma protein and hypermethylation of 14-3-3 sigma gene in salivary gland adenoid cystic carcinoma.

Authors:  D Uchida; N-M Begum; A Almofti; H Kawamata; H Yoshida; M Sato
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.